Get the Stockscreener App
0.6096
1.68%
-0.0104
Pre-market:
.61
0.0004
+0.07%
Tenaya Therapeutics Inc stock is traded at $0.6096, with a volume of 3.72M.
It is down -1.68% in the last 24 hours and down -13.09% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.62
Open:
$0.6273
24h Volume:
3.72M
Relative Volume:
1.71
Market Cap:
$136.69M
Revenue:
-
Net Income/Loss:
$-83.01M
P/E Ratio:
-1.2937
EPS:
-0.4712
Net Cash Flow:
$-64.63M
1W Performance:
-10.26%
1M Performance:
-13.09%
6M Performance:
-15.61%
1Y Performance:
-59.09%
1-Day Range:
$0.60
$0.64
1-Week Range:
$0.60
$0.71
52-Week Range:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.6096 | 136.69M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TENAYA THERAPEUTICS INC (TNYA) Stock Chart - ChartMill
Tenaya Therapeutics, Inc.(NasdaqCM: TNYA) added to S&P Global BMI Index - marketscreener.com
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - investingnews.com
Tenaya Therapeutics Grants 49,000 Shares to CMO Tingley Whittemore (NASDAQ: TNYA) - Kalkine Media
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics CEO Ali Faraz Receives 122,000 Shares and 732,500 Derivative Securities at No Cost (NASDAQ: TNYA) - Kalkine Media
More than 70,000 people in the U.S. are estimated to have a genetic heart condition. A gene therapy for it received special FDA status. - Stock Titan
Tenaya at H.C. Wainwright conference: gene therapy data build By Investing.com - Investing.com UK
A heart-disease biotech will meet investors at two September conferences - Stock Titan
Tenaya Therapeutics (TNYA) Stock Holds Near $0.69 Support Zone as Biotech Faces Key Technical TestMESA MA - siam.in
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - Barchart.com
Israel Englander group takes passive stake in Tenaya Therapeutics (TNYA) - stocktitan.net
Tenaya Therapeutics (TNYA) Falls 3.85% to $0.70 as Shares Approach Critical SupportSynthetic Long - vinanet.vn
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 - MarketBeat
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares By Investing.com - Investing.com Australia
Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock By Investing.com - Investing.com Nigeria
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares - Investing.com
Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock - MarketBeat
Tenaya Therapeutics, Inc. SEC Filing (Aug 18, 2026) - Stock Titan
GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
Tenaya Therapeutics (NASDAQ: TNYA) CEO sells 22K shares to cover RSU taxes - Stock Titan
Tenaya Therapeutics (TNYA) Q2 2026 Earnings: EPS Misses by 186.94% as Clinical-Stage Pipeline Drives Wider-Than-Expected LossRevenue Recognition Risk - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Transcript : Tenaya Therapeutics, Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-11-2026 12 - marketscreener.com
Tenaya Therapeutics (TNYA) Institutional Ownership 2026 - MarketBeat
Tenaya Therapeutics (TNYA) Drops 4% to $0.73 — Testing Crucial Support ZoneADD Alert - Vinanet
TNYA Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Climb on Pipeline OptimismDiluted EPS Report - vinanet.vn
Tenaya Therapeutics at Canaccord Genuity conference: q4 catalysts loom By Investing.com - Investing.com Canada
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings - MarketBeat
Q3 Earnings Forecast for TNYA Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating - moomoo.com
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results - MarketBeat
Tenaya Therapeutics (TNYA) Gains 5.81% as Biotech Stock Holds Above Critical $0.74 SupportZero Gamma Level - dars.gov.et
Tenaya Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Tenaya Therapeutics Q2 net loss widens on impairment charge - TradingView
Tenaya Therapeutics (TNYA) Jumps 5.8% to $0.78 as It Tests Key Resistance at $0.82Calendar Spread Trade - dars.gov.et
Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday - MarketBeat
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Tenaya CFO Eric Hyllengren to Speak at Boston Conference - Stock Titan
Tenaya Therapeutics (TNYA) Steadies Above $0.70 Support as Trading Volume Signals Cautious SentimentStock News - careplusvn.com
Tenaya Therapeutics (TNYA) Slips to $0.74 as Key Support at $0.70 Comes into FocusMutual Fund Flow - careplusvn.com
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TNYA|Tenaya Therapeutics Inc|Price:0.769|Chg%:-0.006 - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):